Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

• by Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie

• June 11, 2026

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

• by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

• July 20, 2026

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

• by Kathryn Wighton

• March 9, 2026

• 3 min

Deep Immunophenotyping Reveals Distinct Immune Signatures in Axial Spondyloarthritis and Psoriatic Arthritis

• by Natalie Frede, Nils Craig-Müller, Silke Kohrt, Marei-Theresa Bott, Ulrich Salzer, Ana Cecilia Venhoff, Jens Thiel, Julia Frede, Reinhard E. Voll, Marta Rizzi, Raquel Lorenzetti, Nils Venhoff

• July 6, 2026